Rhodes Jason P sold $10.7M of DYN (indirect holdings)
Rhodes Jason P sold 504,695 indirectly-held shares of Dyne Therapeutics, Inc. (DYN) at an average of $21.23 ($21.14–$21.28, $10.71M total) across 6 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest actionable element is the just-filed disclosure of a director’s ~$10.7M open-market sale at a narrow price band around $21.2, which can slightly pressure sentiment but is less informative due to pre-arrangement.
Market read
Traders may briefly reassess DYN sentiment on insider-selling optics, but the 10b5-1 structure limits fundamental inference.
What to watch
The disclosure does not state reasons for the sale; traders should check for any concurrent insider buys/sales or other contemporaneous company catalysts before overreacting.
Background
This is an SEC Form 4 insider transaction for Dyne Therapeutics, Inc. (DYN) by director Rhodes Jason P, marked as an indirect holding sale under a Rule 10b5-1 plan.
Ticker impact
Dyne Therapeutics director Rhodes Jason P sold $10.7M of DYN shares via a Rule 10b5-1 plan across 6 trades at ~$21.14–$21.28.
Likely limited near-term impact; any effect should be small and fade unless accompanied by other disclosures.
The filing is a primary Form 4 disclosure with transaction size ($10.7M) and role (director), but the presence of a pre-arranged 10b5-1 plan reduces interpretability as a new bearish thesis.
Market effects
No clear sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a view on Dyne’s prospects.
Key entities
- issuerDyne Therapeutics, Inc.
Subject of the Form 4 insider transaction; director sold 504,695 shares for ~$10.7M under a 10b5-1 plan.
- insiderRhodes Jason P
Director who executed the sales across 2026-06-26 to 2026-06-29; filing made 2026-06-30.
